PP77 Cost-Utility Analysis Of Nivolumab For Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma In The Brazilian Public Healthcare System

Ludmila Gargano, Layssa Oliveira, Haliton Oliveira Junior, Rosa Camila Lucchetta · 2025

Read PP77 Cost-Utility Analysis Of Nivolumab For Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma In The Brazilian Public Healthcare System by Ludmila Gargano, Layssa Oliveira, Haliton Oliveira Junior, Rosa Camila Lucchetta (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768738.txt.

Description

Ludmila Gargano and three co-authors wrote a 2025 study on the value of a drug called nivolumab for head and neck cancer in Brazil's public system. The cancer, which grows in the mouth, throat, and voice box, had in these cases come back or spread after standard drug care. The drug had shown clear survival gains in a major trial.

The team built a model with three states: no growth, growth, and death. Trial data fed the model, and gains were stretched over a five-year span. Costs and quality of life were counted from the public system's view. The drug added about 56,000 dollars in costs per patient over the period, by the model's count. The study weighs those costs against the added years of good life, to guide a funding choice.

Catalog record

CREATORLudmila Gargano, Layssa Oliveira, Haliton Oliveira Junior, Rosa Camila Lucchetta
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12768738

Browse the full library · About the Tower of Babel